HALO - HALOZYME THERAPEUTICS, INC.

70.02
0.620   0.885%

Share volume: 1,660,590
Last Updated: 03-04-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.44%

PREVIOUS CLOSE
CHG
CHG%
$69.40
0.62
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
48%
Profitability 51%
Dept financing 24%
Liquidity 72%
Performance 45%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.24%
1 Month
-10.71%
3 Months
10.56%
6 Months
-6.55%
1 Year
17.62%
2 Year
69.09%
Key data
Stock price
$70.02
P/E Ratio 
24.97
DAY RANGE
$69.38 - $71.53
EPS 
$2.64
52 WEEK RANGE
$47.50 - $82.22
52 WEEK CHANGE
$16.41
MARKET CAP 
7.914 B
YIELD 
N/A
SHARES OUTSTANDING 
118.017 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-05-2025
BETA 
0.88
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,612,075
AVERAGE 30 VOLUME 
$2,196,644
Company detail
CEO: Helen I. Torley
Region: US
Website: halozyme.com
Employees: 390
IPO year: 2004
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company. Its products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL)

Recent news